Latest news with #LCH
Daily Record
27-05-2025
- Health
- Daily Record
Children and teens with four specific cancers wait longer than necessary to be diagnosed
A new study has found that kids and young people wait longer than necessary to receive their cancer diagnoses, depending on the type of cancer they have. New research has revealed that children and young people are waiting longer than necessary to receive cancer diagnoses, particularly if they have four specific types of the disease. Experts at the University of Nottingham have found that young people suffering from certain types of cancer, such as bone tumours, are being affected by lengthy waiting periods before being diagnosed. The new study analysed children's and young peoples' cancer journeys, from the start of their symptoms until they received their cancer diagnosis. Childhood cancer is a global health issue, and early diagnosis is a major priority in combatting it. A team of researchers, led by Dr Shaarna Shanmugavadivel, Professor Shalini Ojha and Professor David Walker from the School of Medicine at the University of Nottingham, collected the data of 1,957 children and young people aged zero to 18 years who were diagnosed with cancer between September 2020 and March 2023. Some cancer types, including Langerhans Cell Histiocytosis (LCH), bone tumours, soft tissue tumours, and brain tumours, were associated with a higher number of medical visits before diagnosis. The Childhood Cancer Diagnosis Study, published in the Lancet Regional Health - Europe, was funded by the National Institute for Health and Care Research (NIHR). Dr Shanmugavadivel said: 'For the first time, we understand the current landscape of childhood cancer diagnosis in the UK. "We can celebrate that ethnicity, sex and socioeconomic status have no impact on time to diagnosis, but there is an urgent need to focus efforts on young people and tumour types such as bone tumours that are still experiencing lengthy intervals. "Earliest possible diagnosis is key as time is crucial. Untreated, tumours grow bigger and can spread around the body, requiring more extensive surgery and more intensive therapies to offer cure.' In the study, the total time from first symptom to confirmed diagnosis varied widely from the same day to several years. The average time to diagnosis was 4.6 weeks, but this varied by age and cancer type. Teenagers aged 15-18 experienced the longest time to diagnosis, which was 8.7 weeks, whereas infants under one year had the shortest at 3.7 weeks. Bone tumours had the longest wait period (12.6 weeks), while kidney tumours had the shortest (2.3 weeks). The number of healthcare visits before a confirmed diagnosis was also examined by the scientists. Most children and young people (74%) had between one and three medical visits before being diagnosed, and two-thirds (67%) were diagnosed in an emergency setting. It became clear that children and young people, particularly teenagers and those with certain types of cancer, experience longer times to diagnosis. 'The findings will help focus efforts towards closing the gap for these groups, ensuring more children and young people receive a diagnosis sooner,' said Dr Shanmugavadivel. 'The results will feed into the Child Cancer Smart campaign led by CCLG: The Children & Young People's Cancer Association, which aims to promote earlier diagnosis, through awareness and education of the public and healthcare professionals.' Ashley Ball-Gamble, CEO of CCLG and co-author on the study, said: 'Childhood cancer knows no boundaries - it affects children and young people of all ages, backgrounds, and walks of life. However, our research has revealed important differences in how long diagnosis takes. "It's crucial that we understand why certain groups, such as older teenagers, or those with certain cancers, such as bone and brain tumours, are likely to face a lengthier diagnosis. By recognising these differences, we hope to work towards faster diagnoses and improved survival rates." Join the Daily Record WhatsApp community!
Business Mayor
23-05-2025
- Automotive
- Business Mayor
Johnson Matthey sells catalyst and process tech business to Honeywell for £1.8bn
JOHNSON MATTHEY is selling its catalyst technologies business to Honeywell for £1.8bn (US$2.4bn). The catalysts technology business designs and licenses process technologies and designs and makes catalysts for processes used in the energy and chemicals industries. This includes the LCH process licensed for use at the blue hydrogen plants being built by bp in Teesside and EET at Stanlow. The business has around 1,900 employees and is headquartered in London with sites in Europe, India and the US. It will be absorbed into the automation business of Honeywell, which includes the US conglomerate's own process technology unit, UOP. Johnson Matthey has been under pressure to change after its largest investor published an open letter in December attacking the performance of the board running the UK-listed chemicals firm. Once the deal is completed, which is expected in the first half of next year, Johnson Matthey will return £1.4bn from the sale to shareholders. 'Today's announcement represents a significant milestone in the history of Johnson Matthey,' said company CEO Liam Condon. 'We will now fundamentally reshape Johnson Matthey into a more focused and leaner business.' The sale of the catalyst technology business, which saw underlying profits rise 23% to £92m last year, will leave Johnson Matthey with three divisions. The largest is its clean air business that makes emissions control catalysts for cars and has seen profits hold steady at £273m. There is the platinum refining business where profits fell 9% to £149m, and the unprofitable green hydrogen technologies unit that lost £39m. In February, following a slump in demand for its green hydrogen technology components, Johnson Matthey cut its investment in the business to the bone. Honeywell expansion and division Honeywell says the purchase will allow it for the first time to offer customers a comprehensive solution for the production of lower emission fuels including methanol, sustainable aviation fuel (SAF), blue hydrogen and blue ammonia. Honeywell CEO Vimal Kapur said: 'The acquisition of Johnson Matthey's Catalyst Technologies business broadens Honeywell's role as a world-class technology provider of critical energy needed to drive growth into the future – further strengthening our model of combining process technologies and process automation.' In February, Honeywell announced plans to sell its aerospace technologies and speciality chemicals divisions to focus on becoming a standalone automation firm. Speaking then, Kapur said: 'Honeywell Automation will create the buildings and industrial infrastructure of the future, leveraging process technology, software, and AI-enabled, autonomous solutions to drive the next generation of productivity, sustainability, and safety…[it] will be better able to capitalise on the global megatrends underpinning its business, from energy security and sustainability to digitalisation and artificial intelligence.' Since December 2023, it has spent US$11bn acquiring other companies including US$1.8bn on the LNG business of Air Products and US$2.1bn on pump manufacturer Sundyne.
South China Morning Post
19-05-2025
- Business
- South China Morning Post
‘Unable to compete': Chinese dismiss India's Prachand combat helicopter against local Z-10
India's new Prachand combat helicopter would be 'a walkover' for China's Z-10 attack helicopter, a Chinese military magazine has claimed of the aircraft New Delhi may turn to for high-altitude operations against its neighbours. The Indian defence ministry in March approved an order for 156 of the helicopters in a contract worth more than US$7.3 billion with an eye to operations at 5,000 metres (16,400 feet) and above, including in the unresolved Himalayan border with China and the Kashmir region dispute with Pakistan. In the latest skirmish in Kashmir last week , India's French-made Rafale fighters were reportedly shot down by Pakistan's Chinese-made J-10C jets. 02:29 Chinese nationalism surges across social media as viral video mocks downed Indian jets Chinese nationalism surges across social media as viral video mocks downed Indian jets The LCH Prachand, meanwhile, is India's first attack helicopter domestically designed and manufactured by the state-owned manufacturer Hindustan Aeronautics Ltd (HAL). It is designed for air-to-ground attack roles, including anti-tank, anti-infantry and close air support. Its first flight was in 2010 and the first batch – 10 for the Indian air force and five for the army – was introduced in 2022. The new order is expected to be delivered between 2028 and 2033. The two-seater lightweight attack helicopter is powered by two turboshaft engines co-developed with the French aerospace company Safran. It features a glass cockpit and low-observable design from lightweight composite materials to endure the monsoon season and achieve a higher service ceiling. Its modern avionics include digital, infrared and laser sensors suite, night vision and an automatic flight control system. The Prachand is equipped with a French M621 20mm cannon and four hardpoints for current and future missiles, including anti-tank, air-to-air and anti-radiation, as well as unguided rockets and bombs, integrated into a helmet-mounted sight control system. However, the Chinese media has questioned how much the helicopter could shift the power balance in high-altitude theatres, claiming that China's Z-10 – already mass deployed in Tibet and Xinjiang facing India – has 'overwhelming advantages' in its protection armour, manoeuvrability and weaponry capacity, in addition to recent improvements, such as a new millimetre-wave radar.
GMA Network
16-05-2025
- Health
- GMA Network
Child with Langerhans cell histiocytosis recovers from disease with GMA Kapuso Foundation's help
An 11-year-old girl diagnosed with Langerhans cell histiocytosis (LCH) has triumphed over the disease with the help of GMA Kapuso Foundation. According to '24 Oras' Friday, Mel Tiangco first met Loanne in 2016 at the tender age of two, fighting the rare disease, looking thin, and having a large abdomen. '[Ang] LCH po kasi meron kang depekto sa cell sa immune system. Kalat 'yan sa buong katawan. Puwede siyang single system, pwede rin siyang multisystem. 'Yung atin pong pasyente, multisystem po siya," pediatric hematologist/oncologist Dr. Michael Cuarteron said. 'Yung bone marrow niya apektado, mababa 'yung red cell niya, mababa din 'yung platelet niya. Tapos 'yung spleen niya, lumaki din 'yun, naapektuhan 'yung liver niya,' he added. Loanne became a beneficiary of the Kapuso Cancer Champions Program in 2016 and received medical treatment through the GMA Kapuso Foundation. Almost a decade later, GMA Kapuso Foundation visited the 11-year-old Loanne, now healthy and vibrant, at her home in Pangasinan. Loanne was also given vitamins, grocery packs, and rice. 'Maraming maraming salamat po sa GMA. Dahil sa inyo, napagamot namin siya nang walang binayaran," Loanne's grandmother, Lani Almojera, said. 'Maraming salamat po sa GMA Kapuso, magaling na po ako. Maraming salamat po kay Tita Mel, dahil natulungan niya ako. Mag-aaral po ako mabuti,' Loanne said. Responding to Loanne, the Kapuso anchor said, 'Walang anuman, Loanne. Masaya ako na makita kang magaling na at sana matupad mo ang iyong mga pangarap.' For those who want to take part in GMA Kapuso Foundation's initiatives, you may send your donations through bank deposits, Cebuana Lhuillier, GCash, Shopee, PayMaya, Zalora, MegaMart, Globe Rewards, Metrobank credit card, and Lazada. For more information, visit the GMA Kapuso Foundation website. —Carby Rose Basina/CDC, GMA Integrated News
Yahoo
15-05-2025
- Business
- Yahoo
Equiduct Expands into the Swiss Market
LONDON, May 15, 2025--(BUSINESS WIRE)--Equiduct, the leading pan-European retail-focused exchange, today announced the launch of its Swiss equity segment, providing retail brokers using Apex with access to 138 of the most liquid Swiss-listed stocks — all priced in Swiss francs (CHF). The newly available securities include heavily traded household names such as Nestlé S.A., Novartis AG, UBS Group AG, and ABB Ltd. Liquidity on the Swiss segment of Equiduct is supported by Apex market makers Virtu Financial, Hudson River Trading, and Optiver. As with all executions on Equiduct, trades on the Swiss segment will benefit from fully interoperable clearing via Equiduct's pan-European network of CCPs: LCH Ltd, Cboe Clear, and the local Swiss CCP SIX x-clear. This expansion follows formal approval from the Swiss Financial Market Supervisory Authority (FINMA), which recognises Börse Berlin and Equiduct as a regulated market under Article 41 of FinfraG. This status also paves the way for Swiss banks and brokers to join Equiduct as direct exchange members, further enhancing best-execution capabilities for Swiss retail brokers and benefiting the Swiss retail investment community. To support the launch of the Swiss segment and Equiduct's growth in the region, the responsibilities of Massimo Formichi Moglia, Head of Italy, have been expanded to include Switzerland — ensuring continuity and leveraging regional synergies. Wail Azizi, Chief Strategy Officer at Equiduct, said: "Our Swiss expansion, backed by formal recognition from FINMA, marks a significant milestone in Equiduct's mission to deliver true pan-European best execution for retail investors and enables us to bring our market-leading, commission-free trading model to one of Europe's most sophisticated markets. By adding Swiss equities to Equiduct, we're also continuing to empower European retail brokers and their clients with broader access, greater transparency, and exceptional execution quality." With the launch of the Swiss market segment, Equiduct now offers commission-free best execution and consolidated market data products for over 1,873 stocks and ETFs across 13 European markets and 18 headline indices. Notes to editors About Equiduct Equiduct is the leading pan-European retail-focused exchange built around the specific needs of the retail community. Equiduct enables retail brokers to achieve Best Execution in Europe's most liquid equities and ETFs across 13 European markets and provides high-quality cost-effective market data and insight products for both the retail community and institutional clients alike. A market segment of Börse Berlin, Equiduct operates under Article 44 of MiFID II. In 2024, Equiduct reported 35 active retail brokers, 15.2 million trades executed, and a turnover of €85 billion. For more information, visit View source version on Contacts For further information, please contact:Massimo Formichi Moglia, Country Head | Italy & SwitzerlandTel: +39 02 12 412 7314Email: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
